Genfit SA Sponsored ADR (GNFTY) Stock
GNFTY is no longer traded. Genfit SA Sponsored ADR was delisted from the Nasdaq in March 2026.
Prices on this page are historical; the last trade was March 9, 2026 at $8.95.
Genfit SA Sponsored ADR stock price history
GNFTY final trading statistics
- Final close
- $8.95
- Final trading day
- Mar 9, 2026
- Market cap at delisting
- $447.83M
- Shares outstanding
- 50.04M
- Final 52-week range
- $2.55 – $10.20
- Avg. volume (final 3 mo.)
- 3,090
- All-time high (split-adj.)
- $26.32 · Mar 2019
- All-time low (split-adj.)
- $2.71 · Apr 2025
- Return since IPO
- -66.0%
- Beta
- 1.19
- Book value / share
- $1.22
- Price / book
- 7.31
Genfit SA Sponsored ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $65.43M | -$86.0M | — |
| FY2024 | $67.00M | $1.5M | — |
| FY2023 | $28.57M | -$28.9M | — |
| FY2022 | $20.20M | -$23.7M | — |
| FY2021 | $80.07M | $67.3M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Genfit SA Sponsored ADR
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Genfit SA Sponsored ADR stock FAQ
What happened to Genfit SA Sponsored ADR stock?
Genfit SA Sponsored ADR stock was delisted from the Nasdaq. Its final close was $8.95 on March 9, 2026.
Is GNFTY stock still trading?
No. GNFTY was delisted from the Nasdaq in March 2026 and no longer trades on a U.S. exchange.
What was the last price of GNFTY stock?
GNFTY closed at $8.95 on its final trading day, March 9, 2026, for a market value of about $447.83M.
What were Genfit SA Sponsored ADR's revenue and earnings in its last full fiscal year?
Genfit SA Sponsored ADR reported revenue of $65.43M and net income of -$86.0M in fiscal 2025, its last full year as a public company.
When did Genfit SA Sponsored ADR go public?
Genfit SA Sponsored ADR stock began trading on March 26, 2019.